Published in Dig Dis Sci on March 01, 2004
What causes alopecia areata? Exp Dermatol (2013) 1.14
Helicobacter pylori eradication shifts monocyte Fcgamma receptor balance toward inhibitory FcgammaRIIB in immune thrombocytopenic purpura patients. J Clin Invest (2008) 0.99
Helicobacter pylori-associated immune thrombocytopenia: clinical features and pathogenic mechanisms. World J Gastroenterol (2014) 0.96
Helicobacter pylori infection and extragastric disorders in children: a critical update. World J Gastroenterol (2014) 0.92
Is there anything to the reported association between Helicobacter pylori infection and autoimmune thyroiditis? Dig Dis Sci (2005) 0.85
Helicobacter pylori infection. N Engl J Med (2002) 14.81
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Association between antibodies to heat shock protein 65 and coronary atherosclerosis. Possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk. Eur Heart J (1998) 1.71
Efficacy of Helicobacter pylori eradication in raising platelet count in adult patients with idiopathic thrombocytopenic purpura. Haematologica (2002) 1.54
Helicobacter pylori infection: pathogenesis. Curr Opin Gastroenterol (2003) 1.45
Is autoimmunity involved in the relationship between Helicobacter pylori infection, atrophic gastritis and gastric cancer? Ital J Gastroenterol Hepatol (1999) 1.40
The Hsp60 protein of Helicobacter pylori: structure and immune response in patients with gastroduodenal diseases. Mol Microbiol (1993) 1.33
Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation (2002) 1.11
Molecular mimicry in Campylobacter jejuni and Helicobacter pylori lipopolysaccharides: contribution of gastrointestinal infections to autoimmunity. J Autoimmun (2001) 1.10
Helicobacter pylori and gastric malignancies. Helicobacter (2002) 1.02
The infection by Helicobacter pylori strains expressing CagA is highly prevalent in women with autoimmune thyroid disorders. J Physiol Pharmacol (1999) 0.93
Helicobacter pylori antigen in the glomeruli of patients with membranous nephropathy. Virchows Arch (1997) 0.91
Review article: immunopathogenetic and therapeutic aspects of autoimmune hepatitis. Aliment Pharmacol Ther (2003) 0.86
Heterogeneity of liver-kidney microsomal autoantibodies in chronic hepatitis C and D virus infection. Gastroenterology (1995) 0.85
Role of antigastric autoantibodies in chronic Helicobacter pylori infection. Microsc Res Tech (2000) 0.85
Helicobacter pylori seroprevalence in patients with autoimmune hepatitis. Dig Dis Sci (2002) 0.82
Eradication of Helicobacter pylori may reduce disease severity in rheumatoid arthritis. Aliment Pharmacol Ther (2002) 0.82
Acute immune polyneuropathies: correlations of serum antibodies to Campylobacter jejuni and Helicobacter pylori with anti-GM1 antibodies and clinical patterns of disease. J Infect Dis (1997) 0.77
Extragastric manifestations of Helicobacter species infection. Do these bacteria act as triggers? Minerva Gastroenterol Dietol (2002) 0.75
Helicobacter pylori infection and autoimmune processes: an emerging field of study. Ital J Gastroenterol Hepatol (1998) 0.75
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology (2003) 9.36
Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology (2002) 6.62
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med (2003) 4.12
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology (2006) 3.80
Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology (2007) 3.78
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med (2005) 3.46
Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology (2002) 3.29
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol (2005) 3.17
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology (2006) 3.14
European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis (2013) 3.01
Ectopic liver and hepatocarcinogenesis: report of three cases with four years' follow-up. Eur J Gastroenterol Hepatol (2004) 2.99
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology (2004) 2.87
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology (2011) 2.86
VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology (2008) 2.53
Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. J Natl Cancer Inst (2005) 2.51
Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol (2006) 2.50
CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol (2009) 2.47
Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology (2003) 2.44
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology (2004) 2.41
Effect of a retrograde-viewing device on adenoma detection rate during colonoscopy: the TERRACE study. Gastrointest Endosc (2010) 2.38
Endoscopic management of GI perforations with a new over-the-scope clip device (with videos). Gastrointest Endosc (2010) 2.38
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26
Safety of endoscopic removal of self-expandable stents after treatment of benign esophageal diseases. Gastrointest Endosc (2013) 2.22
Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. Scand J Gastroenterol (2014) 2.05
Ultraflex precision colonic stent placement as a bridge to surgery in patients with malignant colon obstruction. Gastrointest Endosc (2007) 1.87
A randomized prospective comparison of self-expandable plastic stents and partially covered self-expandable metal stents in the palliation of malignant esophageal dysphagia. Am J Gastroenterol (2007) 1.83
Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol (2010) 1.80
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology (2005) 1.76
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology (2012) 1.76
Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab (2005) 1.73
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology (2009) 1.71
HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol (2012) 1.69
Timing of precut procedure does not influence success rate and complications of ERCP procedure: a prospective randomized comparative study. Gastrointest Endosc (2009) 1.69
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol (2008) 1.69
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl (2005) 1.68
AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol (2007) 1.63
Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology (2008) 1.62
Sightline ColonoSight system for a disposable, power-assisted, non-fiber-optic colonoscopy (with video). Gastrointest Endosc (2008) 1.60
Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol (2008) 1.60
Digestive endoscopy is not a major risk factor for transmitting hepatitis C virus. Ann Intern Med (2005) 1.55
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology (2004) 1.52
Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study. Dig Liver Dis (2011) 1.52
Successful closure of a postsurgical benign esophagomediastinal fistula by temporary placement of a polyester, expandable stent: Case report and review. Gastrointest Endosc (2002) 1.47
A fully-covered stent (Alimaxx-E) for the palliation of malignant dysphagia: a prospective follow-up study. Gastrointest Endosc (2009) 1.47
Italian blood donors with anti-HBc and occult hepatitis B virus infection. Haematologica (2007) 1.47
Temporary placement of an expandable polyester silicone-covered stent for treatment of refractory benign esophageal strictures. Gastrointest Endosc (2004) 1.45
Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease. J Hepatol (2006) 1.43
Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol (2002) 1.43
A predictive model identifies patients most likely to have inadequate bowel preparation for colonoscopy. Clin Gastroenterol Hepatol (2012) 1.42
Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study. Intern Emerg Med (2006) 1.41
Guidelenines in the management of obstructing cancer of the left colon: consensus conference of the world society of emergency surgery (WSES) and peritoneum and surgery (PnS) society. World J Emerg Surg (2010) 1.39
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med (2011) 1.36
New design esophageal stents for the palliation of dysphagia from esophageal or gastric cardia cancer: a randomized trial. Am J Gastroenterol (2007) 1.34
Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol (2008) 1.33
Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol (2003) 1.32
Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J Clin Invest (2007) 1.32
EMR of large sessile colorectal polyps. Gastrointest Endosc (2004) 1.29
Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2005) 1.27
Neuropeptide s receptor 1 gene polymorphism is associated with susceptibility to inflammatory bowel disease. Gastroenterology (2007) 1.24
Glioblastoma cancer stem cells: heterogeneity, microenvironment and related therapeutic strategies. Cell Biochem Funct (2010) 1.20
Type 2 diabetes mellitus and chronic hepatitis C: which is worse? Results of a long-term retrospective cohort study. Dig Liver Dis (2012) 1.19
Ectopic livers and related pathology: report of three cases of benign lesions. Dig Dis Sci (2005) 1.19
Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance. Liver Transpl (2004) 1.14
Capsule enteroscopy vs. other diagnostic procedures in diagnosing obscure gastrointestinal bleeding: a cost-effectiveness study. Eur J Gastroenterol Hepatol (2007) 1.11
Thromboelastogram monitoring in the perioperative period of hepatectomy for adult living liver donation. Liver Transpl (2004) 1.10
Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma in Barrett's esophagus: an Italian experience. World J Gastroenterol (2005) 1.10
Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation. Inflamm Bowel Dis (2005) 1.10
Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol (2006) 1.09
A modified self-expanding Niti-S stent for the management of benign hypopharyngeal strictures. Gastrointest Endosc (2007) 1.09
Polyflex stents for malignant oesophageal and oesophagogastric stricture: a prospective, multicentric study. Eur J Gastroenterol Hepatol (2007) 1.08
Helicobacter species sequences in liver samples from patients with and without hepatocellular carcinoma. World J Gastroenterol (2004) 1.08
Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology (2006) 1.08
Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis (2007) 1.08
Helicobacter species and liver diseases: association or causation? Lancet Infect Dis (2008) 1.08
Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis (2011) 1.07
Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic Biol Med (2012) 1.07